RxDoctor Payments Data

Nicholas Morrow, MD

Family Medicine · Cave Spring, GANPI 1336573757

Payments from drug & device makers

$536in general payments, 2019–2025

Across 18 payments — averaging $29.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$223
  • AstraZeneca$150
  • Mylan Specialty L.p.$50
  • AbbVie$31
  • Viatris Specialty LLC$28
  • Sumitomo Pharma America, Inc.$24
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$536 in reported general payments places this provider in the 45th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$456,495
Medicare patients
937
Services billed
5,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban3,715$676,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter432$208,892
JardianceEmpagliflozin1,059$203,645
OzempicSemaglutide194$199,546
TrulicityDulaglutide203$162,170
XareltoRivaroxaban645$117,364
Tresiba Flextouch U-100Insulin Degludec364$115,881
Invega SustennaPaliperidone Palmitate34$113,588
NuedextaDextromethorphan Hbr/Quinidine138$103,056
LinzessLinaclotide159$92,194
XifaxanRifaximin57$83,212
Incruse ElliptaUmeclidinium Bromide170$65,415
TradjentaLinagliptin403$60,951
Abilify MaintenaAripiprazole12$58,640
Atorvastatin Calcium5,578$54,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$31$122,167251 claims
AstraZenecaFarxiga, Lokelma, Brilinta$150$107,506554 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$223$101,666115 claims
Sumitomo Pharma America, Inc.Gemtesa$24$34,157217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cave Spring

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →